| dbo:abstract |
Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes. The most common side effects include fungal infections of the vagina and other infections of the female reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo. A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan. (en) L'ertugliflozine (nom commercial Steglatro) est un médicament destiné au traitement du diabète de type 2. Aux États-Unis, il a été approuvé par la Food and Drug Administration pour une utilisation en monothérapie et en association à dose fixe avec la sitagliptine ou la metformine. L'agence européenne des médicaments lui a accordé en mars 2018 une AMM au bénéfice du laboratoire Merck Sharp & Dohme, sous forme de comprimés pelliculés dosés à 5 et 15 mg. À partir d'une cohorte de patients atteints d'athérosclérose et de diabète type II, l'ertugliflozine ne provoque pas plus d'effets indésirables graves qu'un placebo. Les effets secondaires les plus courants sont des infections fongiques du vagin et d'autres infections du système reproducteur féminin. L'ertugliflozine est un inhibiteur du cotransporteur sodium/glucose 2 (SGLT2). Elle appartient à la classe des gliflozines. Quatre associations fixes de ertugliflozine et de metformine sont disponibles en Europe sous le nom de spécialité Segluromet, commercialisée par Merck Sharp & Dohme (EMEA/H/C/004314). Deux associations fixes ertugliflozine/sitagliptine sont également commercialisés en Europe, toujours par Merck Sharp & Dohme, sous le nom de spécialité de Steglujan (EMEA/H/C/004313 - IG/1157). (fr) |
| dbo:alternativeName |
Steglatro (en) |
| dbo:casNumber |
1210344-57-2 |
| dbo:class |
dbr:Antidiabetic_agent |
| dbo:drugbank |
DB11827 |
| dbo:fdaUniiCode |
6C282481IP |
| dbo:kegg |
D10313 D11043 |
| dbo:pubchem |
44814423 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Ertugliflozin.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/ertugliflozin |
| dbo:wikiPageID |
56137583 (xsd:integer) |
| dbo:wikiPageLength |
12220 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1102174897 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Enzyme_inhibitor dbr:Blood_plasma dbr:Dehydration dbr:Hypoglycaemia dbr:Cytochrome_P450 dbc:Chloroarenes dbc:Phenol_ethers dbr:Oral_administration dbr:Elimination_half-life dbr:End-stage_renal_disease dbr:Mycosis dbr:Sulfonylurea dbr:Low_blood_pressure dbr:Sitagliptin dbr:Feces dbr:Gliflozin dbc:Anti-diabetic_drugs dbr:Type_2_diabetes dbr:SGLT2 dbr:Faeces dbr:Food_and_Drug_Administration dbr:Glucuronide dbr:Kidney_failure dbr:Hydrolysis dbc:Merck_&_Co._brands dbr:Ketoacidosis dbr:Kidney_dialysis dbr:Diuretics dbr:Placebo dbr:Pharmacokinetic dbr:Insulin_(medication) dbr:Metformin dbc:SGLT2_inhibitors dbr:Medication dbr:UGT2B7 dbr:UGT1A9 dbr:The_New_England_Journal_of_Medicine dbr:Antidiabetic_agent dbr:First-pass_effect dbr:Plasma_protein |
| dbp:atcPrefix |
A10 (en) |
| dbp:atcSuffix |
BK04 (en) |
| dbp:bioavailability |
~100% (en) |
| dbp:c |
22 (xsd:integer) |
| dbp:casNumber |
1210344 (xsd:integer) |
| dbp:chemspiderid |
26340533 (xsd:integer) |
| dbp:cl |
1 (xsd:integer) |
| dbp:class |
dbr:Antidiabetic_agent |
| dbp:dailymedid |
Ertugliflozin (en) |
| dbp:drugbank |
DB11827 (en) |
| dbp:eliminationHalfLife |
61200.0 (dbd:second) |
| dbp:excretion |
41 (xsd:integer) |
| dbp:h |
25 (xsd:integer) |
| dbp:index2Label |
as salt (en) |
| dbp:iupacName |
-5 (xsd:integer) |
| dbp:kegg |
D10313 (en) D11043 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:metabolism |
dbr:UGT2B7 dbr:UGT1A9 |
| dbp:metabolites |
Glucuronides (en) |
| dbp:o |
7 (xsd:integer) |
| dbp:pregnancyAu |
D (en) |
| dbp:proteinBound |
93.6 (dbd:perCent) |
| dbp:pubchem |
44814423 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CCOc1cccCc2cc[C@@]34[C@@H]O (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
MCIACXAZCBVDEE-CUUWFGFTSA-N (en) |
| dbp:synonyms |
PF-04971729, ertugliflozin l-pyroglutamic acid (en) |
| dbp:tradename |
Steglatro (en) |
| dbp:unii |
6 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:See dbt:Use_dmy_dates dbt:Sodium-glucose_transporter_modulators dbt:Drugs.com dbt:Oral_hypoglycemics |
| dct:subject |
dbc:Chloroarenes dbc:Phenol_ethers dbc:Anti-diabetic_drugs dbc:Merck_&_Co._brands dbc:SGLT2_inhibitors |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes. The most common side effects include fungal infections of the vagina and other infections of the female reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan. (en) L'ertugliflozine (nom commercial Steglatro) est un médicament destiné au traitement du diabète de type 2. Aux États-Unis, il a été approuvé par la Food and Drug Administration pour une utilisation en monothérapie et en association à dose fixe avec la sitagliptine ou la metformine. L'agence européenne des médicaments lui a accordé en mars 2018 une AMM au bénéfice du laboratoire Merck Sharp & Dohme, sous forme de comprimés pelliculés dosés à 5 et 15 mg. À partir d'une cohorte de patients atteints d'athérosclérose et de diabète type II, l'ertugliflozine ne provoque pas plus d'effets indésirables graves qu'un placebo. (fr) |
| rdfs:label |
Ertugliflozin (en) Ertugliflozine (fr) |
| owl:sameAs |
wikidata:Ertugliflozin dbpedia-fr:Ertugliflozin dbpedia-hu:Ertugliflozin https://global.dbpedia.org/id/2Y6Y9 |
| prov:wasDerivedFrom |
wikipedia-en:Ertugliflozin?oldid=1102174897&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ertugliflozin.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Ertugliflozin |
| is dbo:wikiPageRedirects of |
dbr:Steglujan dbr:C22H25ClO7 dbr:Ertugliflozin_L-pyroglutamic_acid dbr:Ertugliflozin_L-pyroglutamic_acid,_sitagliptin_phosphate_monohydrate dbr:Ertugliflozin_L-pyroglutamic_acid/metformin_hydrochloride dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin_phosphate dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin_phosphate_monohydrate dbr:Ertugliflozin_l-pyroglutamic_acid/metformin_hydrochloride dbr:Ertugliflozin_pidolate/metformin_hydrochloride dbr:Ertugliflozin/metformin dbr:Ertugliflozin/sitagliptin dbr:Ertugliflozin_l-pyroglutamic_acid/sitagliptin_phosphate_monohydrate dbr:Steglatro dbr:Segluromet dbr:Metformin/ertugliflozin dbr:Ertugliflozin_pidolate |
| is dbo:wikiPageWikiLink of |
dbr:Steglujan dbr:C22H25ClO7 dbr:Ertugliflozin_L-pyroglutamic_acid dbr:Ertugliflozin_L-pyroglutamic_acid,_sitagliptin_phosphate_monohydrate dbr:Ertugliflozin_L-pyroglutamic_acid/metformin_hydrochloride dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin_phosphate dbr:Ertugliflozin_L-pyroglutamic_acid/sitagliptin_phosphate_monohydrate dbr:Ertugliflozin_l-pyroglutamic_acid/metformin_hydrochloride dbr:Ertugliflozin_pidolate/metformin_hydrochloride dbr:Ertugliflozin/metformin dbr:Ertugliflozin/sitagliptin dbr:Ertugliflozin_l-pyroglutamic_acid/sitagliptin_phosphate_monohydrate dbr:Steglatro dbr:ATC_code_A10 dbr:Segluromet dbr:SGLT2_inhibitor dbr:Metformin/ertugliflozin dbr:Ertugliflozin_pidolate |
| is foaf:primaryTopic of |
wikipedia-en:Ertugliflozin |
